ZL-1310 earns fast track designation in extensive-stage small cell lung cancer after early trial data showed tumor shrinkage ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

A deep learning model was able to predict future lung cancer risk from a single low-dose chest CT scan, according to new ...

At 34, non-smoker Reyna Savage mistook persistent shoulder pain for a gym injury, only to be diagnosed with stage 4 non-small ...

Zai Lab Limited ( NASDAQ: ZLAB) said on Monday that it received U.S. FDA fast track designation for its antibody-drug ...

Teos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am ...

A new study published in the Annals of Surgical Oncology revealed that individuals with little muscle mass, segmentectomy ...

The FDA has approved MSD’s Welireg for rare adrenal tumours, and AbbVie’s Emrelis for treating c-Met+ lung cancer patients.

Emrelis is the first FDA-approved treatment for previously treated patients with locally advanced or metastatic non-squamous non-small cell lung cancer with high c-Met protein overexpression.